Fluorescein angiography for the detection of metastases of ovarian tumor in the abdominal cavity, a feasibility pilot

Lasers in Surgery and Medicine

Volumn 35, Issue 5, 2004, Pages 349-353

  Aalders, Maurice C G ^a   Sterenborg, Dick J C M ^b   Van Der Vange, Nine ^c,d  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^d NONE   (Netherlands)

Author keywords

Fluorescein imaging; Metastases; Ovarian tumor; Photodetection

Indexed keywords

FLUORESCEIN SODIUM;

ABDOMINAL ANGIOGRAPHY; ARTICLE; BLOOD VESSEL PERMEABILITY; CLINICAL ARTICLE; DIAGNOSTIC IMAGING; DOSIMETRY; EXTRAVASATION; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; HUMAN CELL; LAPAROSCOPE; METASTASIS; OVARY CANCER; PERITONEAL CAVITY; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; TUMOR BIOPSY; TUMOR VASCULARIZATION;

ABDOMINAL CAVITY; FEASIBILITY STUDIES; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PILOT PROJECTS;

EID: 12444250671     PISSN: 01968092     EISSN: None     Source Type: Journal    
DOI: 10.1002/lsm.20105     Document Type: Article

References (23)

1. Collins PD, Conolly DT, Williams TJ. Characterization of the increase in vascular permeability induced by vascular permeability factor in vivo. Br J Pharmacol 1993;109:195-199.
2. Yuan F, Chen Y, Dellian M, Ferrara N, Jain RK. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci USA 1996;93:14765-14770.
3. Folli S, Pelegrin A, Chalandon Y, Yao X, Buchegger F, Lienard D, Lejeune F. Tumor-necrosis factor can enhance radio-antibody uptake in human colon carcinoma xenografts by increasing vascular permeability. Int J Cancer 1993;53: 829-836.
4. Kohn S, Nagy JA, Dvorak HF, Dvorak AM. Pathways of macromolecular tracer transport across venules and small veins; Structural basis for the hyperpermeability of tumor blood vessels. Lab Invest 1992;67(5):596-607.
5. Andrade SP, Machado RDP, Teixeira AS, Belo AV, Tarso AM, Sponge-Beraldo WT. Induced angiogenesis in mice and the pharmacological reactivity of the neovasculature quantitated by a fluorimetric method. Microvasc Res 1997;54:253-261.
6. Nagy JA, Morgan ES, Herzberg KT, Manseau EJ, Dvorak AM, Dvorak HF. Pathogenesis of ascitis tumor growth: Angiogenesis, vascular remodeling and stroma formation in the peritoneal lining. Cancer Res 1995;55:376-385.
7. Schober R, Vogeley KT, Urich H, Holzle E, Wechsler W. Vascular permeability changes in tumors of the peripheral nervous system. Virchows Archiv A Pathol Anat 1992;420: 59-64.
8. Abu-Jawdeh GM, Faix JD, Niloff J, Tognazzi K, Manseau E, Dvorak HF, Brown LF. Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Lab Invest 1996;6:1105-1115.
9. Larsen M, Loft S, Hommel E, Lund-Andersen H. Fluorescein and fluorescein glucuronide in plasma after intravenous injection of fluorescein. Acta Ophthalmol 1988;66:427-432.
10. Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP, Jain RK. Vascular permeability in a human tumor xenograft: Molecular size dependence and cutoff size. Cancer Res 1995;55:3752-3756.
11. Fleisher AC, Kepple DM. Transvaginal color duplex sonography. Seminars on Ultrasound, CT and MRI 1992;13(1): 69-80.
12. Kawai M, Kikkawa F, Ishikawa H. Differential diagnosis of ovarian tumors by transvaginal color-pulse doppler sonography. Gynecol Oncol 1993;54:209-214.
13. Wu C-C, Lee C-N, Chen T-M, Lai J-I, Hsieh C-Y, Hsieh F-J. Factors contributing to the accuracy in diagnosing ovarian malignancy by color doppler ultrasound. Obstet Gynecol 1994;84:605-608.
14. Droegemueller W. Screening for ovarian cancer: Hopeful and wishful thinking. Am J Obstet Gynecol 1993;170:1095-1098.
15. Brown DL, Frates MC, Laining FC. Ovarian masses: Can benign and malignant lesions be differentiated with color and pulsed doppler US? Radiology 1994;190:333-336.
16. Carter J, Saltzman A, Hartenbach E, Fowler J, Carson L, Twiggs LB. Flow characteristics in benign and malignant gynecologic tumors using transvaginal color flow doppler. Obstet gynecol 1994;83:125-130.
17. Cohen CJ, Jennings TS. Screening for ovarian cancer: The role of noninvasive imaging techniques. Am J Obstet Gynecol 1993;170:1088-1094.
18. Wolf G, Greistorfer K, Stammberger H. Der endoskopische Nachweis von Liquorfisteln mittels der Fluoreszeintechnik. Laryngo-Rhino-Otol 1997;76:588-594.
19. Hochsattel R, Gall H, Weber L, Kaufmann R. Photoallergic reaction to fluorescein. Contact Dermatitis 1990;22:42-44.
20. Kearns GL, Williams BJ, Timmons OD. Fluorescein photo-toxicity in a premature infant. J Pediatr 1985;107(5):796-798.
21. Danis RP, Stephens T. Phototoxic reaction caused by sodium fluorescein. Am J Ophtal 1997;123(5):694-696.
22. Stein MR, Parker CW. Reactions following intravenous fluorescein. Am J Ophtal 1971;72(5):861-868.
23. Desmettre T, Devoisselle JM, Mordon S. Fluorescein properties and metabolic features of indocyanine green (ICG) as related to angiography. Surv Ophthal 2000;45(1):15-27.xxxxxxxxxxx